Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Zhejiang University School of Medicine

Headquarters: Hangzhou, China
Year Founded: 1912
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Mar 26, 2024
Distillery Therapeutics

Fast-acting Kir4.1 inhibitor for depression

BioCentury | Mar 8, 2023
Distillery Therapeutics

A TRPV1 positive allosteric modulator for chronic pain

BioCentury | Jun 2, 2022
Distillery Therapeutics

GPR177 and WNT5A as targets for diabetic neuropathy

BioCentury | Aug 27, 2021
Distillery Therapeutics

Inhibiting NEK2 for pancreatic cancer

BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Dec 2, 2020
Distillery Therapeutics

Apoptosis regulator MCL1 as an Alzheimer’s target

DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease (AD) Blocking MCL1, which inhibits apoptosis, could treat Alzheimer’s disease. A high-throughput screen in HEK cells of
BioCentury | Apr 1, 2020
Distillery Therapeutics

Base editor correction of TERT promoter mutations for glioma

BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH abstracts reveal new mechanisms and consequences of immune cell repolarization in hematology
BioCentury | Apr 30, 2019
Distillery Therapeutics

miR-19a and miR-19b and their mimics for myocardial infarction

BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting EFR3A to treat Alzheimer's disease

Items per page:
1 - 10 of 20